An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders

Cytokine and Growth Factor Reviews

Volumn 26, Issue 1, 2015, Pages 47-57

  Yang, Yang ^a,b   Jiang, Shuai ^a   Yan, Juanjuan ^a   Li, Yue ^a   Xin, Zhenlong ^a   Lin, Yan ^b   Qu, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cerebrum actions; Molecular mechanisms; Neurodegenerative disorders; Nuclear factor erythroid 2 related factor 2

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 (11) DIEN 28 OIC ACID; 2 CYANO 3,12 DIOXOOLEANA 1,9 (11) DIEN 28 OIC ACID ETHYL AMIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 (11) DIEN 28 OIC ACID IMIDAZOLIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 (11) DIEN 28 OIC ACID METHYL AMIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 (11) DIEN 28 OIC ACID TRIFLUOROETHYL AMIDE; ANTIOXIDANT; CULLIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MANGIFERIN; N [4 [2 PYRIDYL] [1,3 THIAZOL 2 YL]] 2 (2,4,6 TRIMETHYLPHENOXY) ACETAMIDE; N,N DIMETHYLFORMAMIDE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; RING BOX 1 PROTEIN; STRATIFIN; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CPG ISLAND; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTONE ACETYLATION; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NUCLEAR EXPORT SIGNAL; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TH17 CELL; UBIQUITINATION; ANIMAL; BRAIN; GENETICS; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; HUMANS; HUNTINGTON DISEASE; MICE; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84923028459     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.09.002     Document Type: Short Survey

References (99)

1. Joshi G., Johnson J.A. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 2012, 7:218-229.
2. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313-322.
3. Sandberg M., Patil J., D'Angelo B., Weber S.G., Mallard C. NRF2-regulation in brain health and disease: implication of cerebral inflammation. Neuropharmacology 2014, 79:298-306.
4. Zhang M., An C., Gao Y., Leak R.K., Chen J., Zhang F. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 2013, 100:30-47.
5. Tasaki M., Kuroiwa Y., Inoue T., Hibi D., Matsushita K., Kijima A., et al. Lack of Nrf2 results in progression of proliferative lesions to neoplasms induced by long-term exposure to non-genotoxic hepatocarcinogens involving oxidative stress. Exp Toxicol Pathol 2014, 6:19-26.
6. Sahu B.D., Kuncha M., Rachamalla S.S., Sistla R. Lagerstroemia speciosa L, attenuates apoptosis in isoproterenol-induced cardiotoxic mice by inhibiting oxidative stress: possible role of Nrf2/HO-1. Cardiovasc Toxicol 2014, [Epub ahead of print].
7. Aminzadeh M.A., Reisman S.A., Vaziri N.D., Khazaeli M., Yuan J., Meyer C.J. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica 2014, 44:570-578.
8. Hyeon S., Lee H., Yang Y., Jeong W. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Free Radic Biol Med 2013, 65:789-799.
9. Song J., Kang S.M., Lee W.T., Park K.A., Lee K.M., Lee J.E. Glutathione protects brain endothelial cells from hydrogen peroxide-induced oxidative stress by increasing nrf2 expression. Exp Neurobiol 2014, 23:93-103.
10. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24:7130-7139.
11. Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 2005, 280:30091-30099.
12. Zhang D.D., Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003, 23:8137-8151.
13. McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 2006, 281:24756-24768.
14. Eggler A.L., Liu G., Pezzuto J.M., van Breemen R.B., Mesecar A.D. Modifying specific cysteines of the electrophilie-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad SCi USA 2005, 102:10070-10075.
15. Zipper L.M., Mulcahy R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 2002, 277:36544-36552.
16. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 2004, 378:373-382.
17. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 2007, 282:2529-2537.
18. Theodore M., Kawai Y., Yang J., Kleshchenko Y., Reddy S.P., Villalta F., et al. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem 2008, 283:8984-8994.
19. Li W., Kong A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 2009, 48:91-104.
20. Bloom D.A., Jaiswal A.K. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 2003, 278:44675-44682.
21. Rushmore T.H., Morton M.R., Pickett C.B. The antioxidant responsive element Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991, 266:11632-11639.
22. Copple I.M., Goldring C.E., Kitteringham N.R., Park B.K. The Nrf2-Keap1 defense pathway: role in protection against drug-induced toxicity. Toxicology 2008, 246:24-33.
23. Kwak M.K., Wakabayashi N., Greenlaw J.L., Yamamoto M., Kensler T.W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 2003, 23:8786-8794.
24. Kaspar J.W., Jaiswal A.K. An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. J Biol Chem 2010, 285:21349-21358.
25. Rada P., Rojo A.I., Evrard-Todeschi N., Innamorato N.G., Cotte A., Jaworski T., et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol 2012, 32:3486-3499.
26. Jain A.K., Jaiswal A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 2007, 282:16502-16510.
27. Niture S.K., Jaiswal A.K. Prothymosin-alpha mediates nuclear import of the INrf2/Cul3 Rbx1 complex to degrade nuclear Nrf2. J Biol Chem 2009, 284:13856-13868.
28. Chen W., Sun Z., Wang X.J., Jiang T., Huang Z., Fang D., et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009, 34:663-673.
29. Ichimura Y., Waguri S., Sou Y.S., Kageyama S., Hasegawa J., Ishimura R., et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013, 51:618-631.
30. Jyrkkanen H.K., Kuosmanen S., Heinaniemi M., Laitinen H., Kansanen E., Mella-Aho E., et al. Novel insights into the regulation of antioxidant-response-element-mediated gene expression by electrophiles: induction of the transcriptional repressor BACH1 by Nrf2. Biochem J 2011, 440:167-174.
31. Zou W., Chen C., Zhong Y., An J., Zhang X., Yu Y., et al. PI3K/Akt pathway mediates Nrf2/ARE activation in human L02 hepatocytes exposed to low-concentration HBCDs. Environ Sci Technol 2013, 47:12434-12440.
32. Meng X.B., Sun G.B., Wang M., Sun J., Qin M., Sun X.B. P90RSK and Nrf2 activation via MEK1/2-ERK1/2 pathways mediated by notoginsenoside R2 to prevent 6-hydroxydopamine-induced apoptotic death in SH-SY5Y cells. Evid Based Complement Alternat Med 2013, 2013:971712.
33. Kalinin S., Polak P.E., Lin S.X., Braun D., Guizzetti M., Zhang X., et al. Dimethyl fumarate regulates histone deacetylase expression in astrocytes. J Neuroimmunol 2013, 263:13-19.
34. Wu T.Y., Khor T.O., Su Z.Y., Saw C.L., Shu L., Cheung K.L., et al. Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J 2013, 15:864-874.
35. Gan L., Johnson J.A. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim Biophys Acta 2013, 1842:1208-1218.
36. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001, 98:3410-3415.
37. Imaizumi Y., Okada Y., Akamatsu W., Koike M., Kuzumaki N., Hayakawa H., et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 2012, 5:35.
38. Chaturvedi R.K., Flint Beal M. Mitochondrial diseases of the brain. Free Radic Biol Med 2013, 63:1-29.
39. Miller D.M., Singh I.N., Wang J.A., Hall E.D. Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo. Free Radic Biol Med 2013, 57:1-9.
40. Aki T., Funakoshi T., Unuma K., Uemura K. Impairment of autophagy: from hereditary disorder to drug intoxication. Toxicology 2013, 311:205-215.
41. Komatsu M., Kurokawa H., Waguri S., Taguchi K., Kobayashi A., Ichimura Y., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010, 12:213-223.
42. Lau A., Wang X.J., Zhao F., Villeneuve N.F., Wu T., Jiang T., et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 2010, 30:3275-3285.
43. Correa F., Mallard C., Nilsson M., Sandberg M. Dual TNFalpha-induced effects on NRF2 mediated antioxidant defence in astrocyte-rich cultures: role of protein kinase activation. Neurochem Res 2012, 37:2842-2855.
44. Nair S., Doh S.T., Chan J.Y., Kong A.N., Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 2008, 99:2070-2082.
45. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008, 181:680-689.
46. Li B., Cui W., Liu J., Li R., Liu Q., Xie X.H., et al. Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice. Exp Neurol 2013, 250:239-249.
47. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernandez-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 2011, 14:2347-2360.
48. Tarozzi A., Angeloni C., Malaguti M., Morroni F., Hrelia S., Hrelia P. Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid Med Cell Longev 2013, 2013:415078.
49. Greco T., Fiskum G. Brain mitochondria from rats treated with sulforaphane are resistant to redox-regulated permeability transition. J Bioenerg Biomembr 2010, 42:491-497.
50. Hutchinson M., Fox R.J., Havrdova E., Kurukulasuriya N.C., Sarda S.P., Agarwal S., et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014, 30:613-627.
51. Lee D.H., Gold R., Linker R.A. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012, 13:11783-11803.
52. Scannevin R.H., Chollate S., Jung M.Y., Shackett M., Patel H., Bista P., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012, 341:274-284.
53. Liby K., Hock T., Yore M.M., Suh N., Place A.E., Risingsong R., et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005, 65:4789-4798.
54. Pareek T.K., Belkadi A., Kesavapany S., Zaremba A., Loh S.L., Bai L., et al. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci Rep 2011, 1:201.
55. Yang L., Calingasan N.Y., Thomas B., Chaturvedi R.K., Kiaei M., Wille E.J., et al. Neuroprotective effects of the triterpenoid CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE 2009, 4:e5757.
56. Raju V.S., Maines M.D. Coordinated expression and mechanism of induction of HSP32 (heme oxygenase-1) mRNA by hyperthermia in rat organs. Biochim Biophys Acta 1994, 1217:273-280.
57. Everse J., Coates P.W. Neurodegeneration and peroxidases. Neurobiol Aging 2009, 30:1011-1025.
58. Deguchi K., Hayashi T., Nagotani S., Sehara Y., Zhang H., Tsuchiya A., et al. Reduction of cerebral infarction in rats by biliverdin associated with amelioration of oxidative stress. Brain Res 2008, 1188:1-8.
59. Cuadrado A., Rojo A.I. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 2008, 14:429-442.
60. Zhou Y., Xie N., Li L., Zou Y., Zhang X., Dong M. Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice. Int J Neuropsychopharmacol 2014, 17:635-644.
61. Song W., Zukor H., Liberman A., Kaduri S., Arvanitakis Z., Bennett D.A., et al. Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Exp Neurol 2014, 254:78-89.
62. Iyanagi T., Yamazaki I. One-electron-transfer reactions in biochemical systems, V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim Biophys Acta 1970, 216:282-294.
63. Zhang B.P., Zhao J., Li S.S., Yang L.J., Zeng L.L., Chen Y., et al. Mangiferin activates Nrf2-antioxidant response element signaling without reducing the sensitivity to etoposide of human myeloid leukemia cells in vitro. Acta Pharmacol Sin 2014, 35:257-266.
64. Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., Rabano A., Kirik D., et al. alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 2012, 21:3173-3192.
65. Kwon J., Han E., Bui C.B., Shin W., Lee J., Lee S., et al. Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade. EMBO Rep 2012, 13:150-156.
66. Powis G., Montfort W.R. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001, 30:421-455.
67. Rybnikova E., Damdimopoulos A.E., Gustafsson J.A., Spyrou G., Pelto-Huikko M. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci 2000, 12:1669-1678.
68. Lippoldt A., Padilla C.A., Gerst H., Andbjer B., Richter E., Holmgren A., et al. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 1995, 15:6747-6756.
69. Andoh T., Chock P.B., Chiueh C.C. The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J Biol Chem 2002, 277:9655-9660.
70. Im J.Y., Lee K.W., Woo J.M., Junn E., Mouradian M.M. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet 2012, 21:3013-3024.
71. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
72. Loewen C.A., Feany M.B. The unfolded protein response protects from tau neurotoxicity in vivo. PLoS ONE 2010, 5.
73. Eftekharzadeh B., Maghsoudi N., Khodagholi F. Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie 2010, 92:245-253.
74. Kim H.V., Kim H.Y., Ehrlich H.Y., Choi S.Y., Kim D.J., Kim Y. Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 2013, 20:7-12.
75. Dumont M., Wille E., Calingasan N.Y., Tampellini D., Williams C., Gouras G.K., et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J Neurochem 2009, 109:502-512.
76. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
77. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
78. La Quaglia M.P., Manchester K.M. A comparative analysis of neuroblastic and substrate-adherent human neuroblastoma cell lines. J Pediatr Surg 1996, 31:315-318.
79. Niso-Santano M., Gonzalez-Polo R.A., Bravo-San Pedro J.M., Gomez-Sanchez R., Lastres-Becker I., Ortiz-Ortiz M.A., et al. Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. Free Radic Biol Med 2010, 48:1370-1381.
80. Lou H., Jing X., Wei X., Shi H., Ren D., Zhang X. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacology 2014, 79:380-388.
81. Siebert A., Desai V., Chandrasekaran K., Fiskum G., Jafri M.S. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 2009, 87:1659-1669.
82. Kumar P., Kalonia H., Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep 2010, 62:1-14.
83. Jin Y.N., Yu Y.V., Gundemir S., Jo C., Cui M., Tieu K., et al. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS ONE 2013, 8:e57932.
84. Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 2011, 6:e16172.
85. Stack C., Ho D., Wille E., Calingasan N.Y., Williams C., Liby K., et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 2010, 49:147-158.
86. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
87. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-945.
88. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
89. Johnson D.A., Amirahmadi S., Ward C., Fabry Z., Johnson J.A. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 2010, 114:237-246.
90. Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
91. Kanno T., Tanaka K., Yanagisawa Y., Yasutake K., Hadano S., Yoshii F., et al. A novel small molecule, N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide, selectively protects against oxidative stress-induced cell death by activating the Nrf2-ARE pathway: therapeutic implications for ALS. Free Radic Biol Med 2012, 53:2028-2042.
92. Mimoto T., Miyazaki K., Morimoto N., Kurata T., Satoh K., Ikeda Y., et al. Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res 2012, 1446:109-118.
93. Duan W., Li X., Shi J., Guo Y., Li Z., Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience 2010, 169:1621-1629.
94. Kim S.W., Lee H.K., Shin J.H., Lee J.K. Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving It from p65. Free Radic Biol Med 2013, 65:468-476.
95. Habas A., Hahn J., Wang X., Margeta M. Neuronal activity regulates astrocytic Nrf2 signaling. Proc Natl Acad Sci U S A 2013, 110:18291-18296.
96. Jin M.L., Park S.Y., Kim Y.H., Park G., Lee S.J. Acanthopanax senticosus exerts neuroprotective effects through HO-1 signaling in hippocampal and microglial cells. Environ Toxicol Pharmacol 2013, 35:335-346.
97. Li R., Liang T., Xu L., Zheng N., Zhang K., Duan X. Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway. Brain Res 2013, 1523:1-9.
98. Wang R., Tu J., Zhang Q., Zhang X., Zhu Y., Ma W., et al. Genistein attenuates ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO-1 signaling. Hippocampus 2013, 23:634-647.
99. Farr S.A., Ripley J.L., Sultana R., Zhang Z., Niehoff M.L., Platt T.L., et al. Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 2014, 67:387-395.